Cargando…

Controlled hypotension for FESS: A randomised double-blinded comparison of magnesium sulphate and dexmedetomidine

BACKGROUND AND AIMS: Intense bleeding during general anaesthesia (GA) is the major limitation during functional endoscopic sinus surgery (FESS). This study was aimed to compare the efficacy of dexmedetomidine and magnesium sulphate (MgSO(4)) for controlled hypotension in FESS. METHODS: Sixty eight p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chhabra, Alka, Saini, Preeti, Sharma, Karuna, Chaudhary, Neelam, Singh, Abhineet, Gupta, Sunanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967369/
https://www.ncbi.nlm.nih.gov/pubmed/32001905
http://dx.doi.org/10.4103/ija.IJA_417_19
_version_ 1783488937605464064
author Chhabra, Alka
Saini, Preeti
Sharma, Karuna
Chaudhary, Neelam
Singh, Abhineet
Gupta, Sunanda
author_facet Chhabra, Alka
Saini, Preeti
Sharma, Karuna
Chaudhary, Neelam
Singh, Abhineet
Gupta, Sunanda
author_sort Chhabra, Alka
collection PubMed
description BACKGROUND AND AIMS: Intense bleeding during general anaesthesia (GA) is the major limitation during functional endoscopic sinus surgery (FESS). This study was aimed to compare the efficacy of dexmedetomidine and magnesium sulphate (MgSO(4)) for controlled hypotension in FESS. METHODS: Sixty eight patients undergoing FESS were randomised to receive either dexmedetomidine 1 μg/kg over 10 min followed by infusion at 0.2 to 0.7 μg/kg/h (Group D) or MgSO(4) 40 mg/kg over 10 min followed by an infusion at 10 to 15 mg/kg/h (Group M). Anaesthesia and infusion rates for study drugs were maintained with sevoflurane to keep MAP between 60–70 mmHg throughout the surgery. The time to reach the target MAP, the number of patients requiring a minimum and maximum infusion doses of study drugs were noted. RESULTS: The mean time to achieve target mean arterial pressure (MAP) was less in group D (10.59 ± 2.04) as compared with (21.32 ± 4.65 min) group M (P < 0.001). The target MAP was achieved between 5–15 min in 73.52% patients (Group D) with an infusion dose of 0.2–0.4 μg/kg/h of dexmedetomidine without the use of sevoflurane, while 82.35% patients in group M required 4% sevoflurane along with >12–15 mg/kg/hr infusion of MgSO(4) to achieve target MAP in 10–20 min. CONCLUSION: Dexmedetomidine is superior to MgSO(4) in achieving target MAP in lesser time with minimum infusion dose.
format Online
Article
Text
id pubmed-6967369
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-69673692020-01-30 Controlled hypotension for FESS: A randomised double-blinded comparison of magnesium sulphate and dexmedetomidine Chhabra, Alka Saini, Preeti Sharma, Karuna Chaudhary, Neelam Singh, Abhineet Gupta, Sunanda Indian J Anaesth Original Article BACKGROUND AND AIMS: Intense bleeding during general anaesthesia (GA) is the major limitation during functional endoscopic sinus surgery (FESS). This study was aimed to compare the efficacy of dexmedetomidine and magnesium sulphate (MgSO(4)) for controlled hypotension in FESS. METHODS: Sixty eight patients undergoing FESS were randomised to receive either dexmedetomidine 1 μg/kg over 10 min followed by infusion at 0.2 to 0.7 μg/kg/h (Group D) or MgSO(4) 40 mg/kg over 10 min followed by an infusion at 10 to 15 mg/kg/h (Group M). Anaesthesia and infusion rates for study drugs were maintained with sevoflurane to keep MAP between 60–70 mmHg throughout the surgery. The time to reach the target MAP, the number of patients requiring a minimum and maximum infusion doses of study drugs were noted. RESULTS: The mean time to achieve target mean arterial pressure (MAP) was less in group D (10.59 ± 2.04) as compared with (21.32 ± 4.65 min) group M (P < 0.001). The target MAP was achieved between 5–15 min in 73.52% patients (Group D) with an infusion dose of 0.2–0.4 μg/kg/h of dexmedetomidine without the use of sevoflurane, while 82.35% patients in group M required 4% sevoflurane along with >12–15 mg/kg/hr infusion of MgSO(4) to achieve target MAP in 10–20 min. CONCLUSION: Dexmedetomidine is superior to MgSO(4) in achieving target MAP in lesser time with minimum infusion dose. Wolters Kluwer - Medknow 2020-01 2020-01-07 /pmc/articles/PMC6967369/ /pubmed/32001905 http://dx.doi.org/10.4103/ija.IJA_417_19 Text en Copyright: © 2020 Indian Journal of Anaesthesia http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Chhabra, Alka
Saini, Preeti
Sharma, Karuna
Chaudhary, Neelam
Singh, Abhineet
Gupta, Sunanda
Controlled hypotension for FESS: A randomised double-blinded comparison of magnesium sulphate and dexmedetomidine
title Controlled hypotension for FESS: A randomised double-blinded comparison of magnesium sulphate and dexmedetomidine
title_full Controlled hypotension for FESS: A randomised double-blinded comparison of magnesium sulphate and dexmedetomidine
title_fullStr Controlled hypotension for FESS: A randomised double-blinded comparison of magnesium sulphate and dexmedetomidine
title_full_unstemmed Controlled hypotension for FESS: A randomised double-blinded comparison of magnesium sulphate and dexmedetomidine
title_short Controlled hypotension for FESS: A randomised double-blinded comparison of magnesium sulphate and dexmedetomidine
title_sort controlled hypotension for fess: a randomised double-blinded comparison of magnesium sulphate and dexmedetomidine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967369/
https://www.ncbi.nlm.nih.gov/pubmed/32001905
http://dx.doi.org/10.4103/ija.IJA_417_19
work_keys_str_mv AT chhabraalka controlledhypotensionforfessarandomiseddoubleblindedcomparisonofmagnesiumsulphateanddexmedetomidine
AT sainipreeti controlledhypotensionforfessarandomiseddoubleblindedcomparisonofmagnesiumsulphateanddexmedetomidine
AT sharmakaruna controlledhypotensionforfessarandomiseddoubleblindedcomparisonofmagnesiumsulphateanddexmedetomidine
AT chaudharyneelam controlledhypotensionforfessarandomiseddoubleblindedcomparisonofmagnesiumsulphateanddexmedetomidine
AT singhabhineet controlledhypotensionforfessarandomiseddoubleblindedcomparisonofmagnesiumsulphateanddexmedetomidine
AT guptasunanda controlledhypotensionforfessarandomiseddoubleblindedcomparisonofmagnesiumsulphateanddexmedetomidine